• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Zeposia will Flop. Fallout will affect many

The timing is fortune. Out of everyone’s control.

but there is no real access and the providers have no time for switching or talking new therapies.
Yes yes we know done have will the ones I’m out pocket but overall this launch will flop.
 












Product profile better than anticipated. Our problem has been personnel all along. We had a chance to put the right people in place to create a "sales" culture and we let Todd do his thing for too long. We passed on the right people in the name of those he knew. Things flow downhill from there. Then the merger. Some of the very best were precluded from coming with us because they were Otezla people. If we had their top 20% (who were all willing to come), we would be fine. Instead, we are surrounded by Jason and Todd types. When you combine that with the BMY culture of activity over performance, it gets rotten quick. I am hoping to hold on through COVID and then get out.
 
































I am a competitor in the West Coast and I can say that nobody is writing this. Its so bad that I feel sorry for the rep. Zeposia is a decent drug but not able to find a niche.
 




















I can definitely say that OFA is killing here in S. CA and I’m probably gonna need to be looking for a new gig soon. All of those east coaster/south/Midwest—are you seeing OFA taking off in your area?
 












Just saw job posting for Gastro position in my area. Thinking comp is base of 140-160 with total payout 180-200. Just wondering if this accurate info as I don’t want to leave current job for less. Would appreciate any insight into what accurate comp is for this role. Thank You